A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial
Letter
[키워드] 24 hour
48 hour
Activation
acute lung injury
acute pneumonia
acute respiratory distress syndrome
Administered
Adult
age
all-cause mortality
Amendment
antibodies
antibody
Antibody test
anticipated
antiviral therapy
approval
ARDS
assessment
assigned
baseline
Biomarker
Blood
cardiac disease
Care
change
class
Clinical improvement
clinical study
clinical trial
complement
Complement inhibitor
component
Computed tomography
concealed
Concentration
conducted
Confirmed
Controlled
coronary syndrome
COVID-19
criteria
current
Day
diagnosis of SARS-CoV-2
dialysis
discharge
dissemination
dose
Duration
Efficacy
element
eligibility
Endotracheal intubation
EU Clinical Trial
EudraCT
evaluate the effect
expected
failure
female patient
Final
fraction
France
Germany
greater
half-live
hospital
Hospitalization
humanized
Hypercoagulable state
Immunoglobulin
Infection
Inflammatory
inhibitor
initiated
intensive care
Intubated
intubation
invasive
Invasive mechanical ventilation
investigator
IVIG
Japan
Lung injury
mechanical ventilation
medication
monoclonal
multicenter
Neisseria meningitidis
Non-invasive
number
objective
Open-label
original
outcome
oxygen
participant
Patient
patients randomized
patients with COVID-19
Period
peripheral capillary
phase
Placebo
Pneumonia
polymerase chain
positive airway pressure
presenting
progression
protocol
randomised
randomised controlled trial
randomization
randomization list
Randomized
randomized controlled study
Randomly
Ravulizumab
receive
recruitment
registry
Remdesivir
renal
respiratory
respiratory distress
Respiratory distress syndrome
routine clinical care
Safety
screened
Screening
secondary
Serious Adverse Events
serum
severe acute respiratory distress syndrome coronavirus 2
Severe acute respiratory syndrome
severe COVID-19
severe pneumonia
SOFA
Spain
SpO2
Sponsor
stratified
Study protocol
supportive care
survival
The United States
therapy
time
Treatment
treatment-emergent adverse event
Ultomiris
United Kingdom
ventricular
Viral
website
with COVID-19
X-ray
[DOI] 10.1186/s13063-020-04548-z PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04548-z PMC 바로가기 [Article Type] Letter